Pharma Pulse: Mark Cuban Disrupts Drug Pricing, AstraZeneca Expands US Manufacturing, and BMS Bets Big on RNA Therapeutics

This episode of Pharma Pulse covers how Mark Cuban’s direct-to-consumer pharmacy is challenging traditional drug pricing models, AstraZeneca’s $4.5 billion investment to expand its Virginia manufacturing site, and Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics to advance RNA-based medicines.